Jump to content

Stephen Tsang

Add links
From Wikipedia, the free encyclopedia
For the SOAS political scientist and historian, see Steve Tsang.
Stephen H. Tsang
曾慶霖
Born
British Hong Kong
EducationJohns Hopkins University (B.S.), Columbia College of Physicians and Surgeons (M.D.–Ph.D.)
Scientific career
Fieldsophthalmology, genetics
InstitutionsColumbia University Irving Medical Center

Stephen H. Tsang (Chinese: 曾慶霖; Pinyin: Zeng Qing-Lin) is an American ophthalmologist and geneticist. He is currently a Professor of Ophthalmology, and Pathology and Cell Biology at Columbia University Irving Medical Center in New York.[1]

Career

[edit]

Professor Tsang studies metabolic signaling in retinal diseases, as well as gene therapy and stem cell therapy to treat such diseases.[2][3][4][5] In 2010, Tsang led an international research team that used embryonic stem cells of mice to replace diseased retinal cells in mice with retinitis pigmentosa to restore sight.[6] In 2012, Tsang produced long term visual improvement in retinitis pigmentosa mouse models in two experiments, one using induced pluripotent stem cells and the other gene therapy.[7] In 2015, Tsang was among the leaders of a team which discovered a gene mutation that can cause achromatopsia.[1] In 2016, Tsang's team, in partnership with University of Iowa scientists, used the genome editing tool called CRISPR to repair a mutation that causes retinitis pigmentosa in patient derived stem cells.[8][9][10] In 2018, Tsang and his team created a new technique for CRISPR, restoring function in the retina of mice affected by retinitis pigmentosa.[3][6][11]

Tsang is a member of the Scientific Advisory Panel of Research to Prevent Blindness effective until 2029.[12] He is also a standing member of the Pathophysiology of Eye Disease - 2 study section until 2026 [13] and a member of the Alcon Research Institute Grants Review Committee.[14]

Tsang is the editor of three books on regenerative medicine and precision medicine.[15][16][17][18] He also edited a book on inherited retinal diseases.[19] He has authored over 280 peer-reviewed articles, including articles published in Science, Journal of Clinical Investigation, and the New England Journal of Medicine.[20][21]

Education

[edit]

Tsang was born in British Hong Kong's Evangel Hospital 播道醫院. He went to St. Teresa's Kindergarten and St. Teresa's Primary School (STS, 九龍聖德肋撒英文學校), then onto La Salle College, all in Kowloon, Hong Kong. He immigrated to the United States after La Salle College, graduating from Johns Hopkins University.[22]

During college, Tsang trained in medical genetics under Professor Victor A. McKusick.[23] He obtained an M.D.-Ph.D. from the NIH-National Institute of General Medical Sciences Medical Scientist Training Program at Columbia University.[23] Tsang did his residency at Jules Stein Eye Institute/UCLA, and then he studied with Professors Alan C. Bird and Graham E. Holder, researching how to improve care of people suffering from macular degeneration.[1]

References

[edit]
  1. ^ a b c "Stephen H. Tsang, MD, PhD". Pathology. 2017-06-21. Retrieved 2018-07-11.
  2. ^ "Scientists foresee fixes even for complicated forms of blindness". NBC News. Retrieved 2018-07-11.
  3. ^ a b "Genome Surgery for Eye Disease Moves Closer to Reality – American Academy of Ophthalmology". www.aao.org. 11 May 2018. Retrieved 2018-07-11.
  4. ^ "Stephen Tsang | NYSTEM". stemcell.ny.gov. Retrieved 2018-07-11.
  5. ^ [CUMC press office] (1 June 2015). New Color Blindness Cause Identified Finding Suggests Potential Therapeutic Targets. States News Service. Accessed November 2015. (subscription required)
  6. ^ a b "Columbia University Medical Center Press Release". www.cumc.columbia.edu. Retrieved 2018-07-11.
  7. ^ "Two Treatments for Retinitis Pigmentosa Move Closer to Clinical Trials – Columbia University Medical Center". Columbia University Medical Center. 2012-12-20. Retrieved 2018-07-11.
  8. ^ "Combination of Stem Cells and Gene Modifying Tools Provide Path to Vision Repair | NYSTEM". stemcell.ny.gov. Retrieved 2018-07-11.
  9. ^ Mullin, Emily. "CRISPR Used To Repair Blindness-Causing Gene Defect". Forbes. Retrieved 2018-07-19.
  10. ^ ""Genome Surgery" Edits out Progressive Blindness in Mice". Genomics Research from Technology Networks. Retrieved 2019-06-18.
  11. ^ "Synthego | Full Stack Genome Engineering". www.synthego.com. Retrieved 2019-06-19.
  12. ^ "Research to Prevent Blindness: Scientific Advisory Panel". www.rpbusa.org/rpb/.
  13. ^ "Pathophysiology of Eye Disease - 2 Study Section".
  14. ^ "·2022-2023 ARI Committee Members" (PDF).
  15. ^ Precision Medicine, CRISPR, and Genome Engineering – Moving from Association to Biology and Therapeutics | Stephen Tsang | Springer.
  16. ^ "Recent book publication edited by Dr. Stephen Tsang". Columbia Stem Cell Initiative – CSCI. 2017-12-05. Retrieved 2018-07-11.
  17. ^ Stem Cell Biology and Regenerative Medicine in Ophthalmology | Stephen Tsang | Springer.
  18. ^ CRISPR Genome Surgery in Stem Cells and Disease Tissues | Stephen Tsang | Elsevier.
  19. ^ Atlas of Inherited Retinal Diseases | Stephan Tsang and Tarun Sharma | Springer. Advances in Experimental Medicine and Biology. Vol. 1085. 2018. doi:10.1007/978-3-319-95046-4. ISBN 978-3-319-95045-7. S2CID 58887054.
  20. ^ pubmeddev. "tsang sh – PubMed – NCBI". www.ncbi.nlm.nih.gov. Retrieved 2018-07-13.
  21. ^ Oh, J. K.; Tsang, S. H. (2020). "Oh, J. K., & Tsang, S. H. (2020). Stargardt Juvenile Macular Degeneration. New England Journal of Medicine, 382(24), 2353–2353. Doi:10.1056/nejmicm1913388". The New England Journal of Medicine. 382 (24): 2353. doi:10.1056/NEJMicm1913388. PMID 32521136. S2CID 219586610.
  22. ^ "Stephen H. Tsang, MD, PhD". Institute of Genomic Medicine. Retrieved 2018-07-11.
  23. ^ a b "Columbia Ophthalmology". www.columbiaeye.org. Retrieved 2018-07-11.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Stephen_Tsang&oldid=1186414375"